A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir
- First Online:
- 284 Downloads
Doravirine, a non-nucleoside reverse-transcriptase inhibitor in development for the treatment of patients with human immunodeficiency virus-1 infection, has potential to be used concomitantly in antiretroviral therapy with dolutegravir, an integrase strand transfer inhibitor. The pharmacokinetic interactions between these drugs were therefore assessed.
Oral formulations of doravirine and dolutegravir were dosed both individually and concomitantly once daily in healthy adults. Twelve subjects (six were male), 23–42 years of age, were enrolled and 11 completed this phase I, open-label, three-period, fixed-sequence study per protocol; one subject was discontinued for a positive cotinine test at admission to period 2. In period 1, dolutegravir 50 mg was administered for 7 days. After a 7-day washout, doravirine 200 mg was dosed for 7 days in period 2, followed (without washout) by both doravirine and dolutegravir simultaneously for 7 days in period 3. Plasma samples were taken to determine dolutegravir and doravirine concentrations.
The steady-state concentration 24 h post-dose (C24) of dolutegravir was not substantially altered by co-administration of doravirine multiple doses; area under the plasma concentration–time curve from dosing to 24 h post-dose (AUC0–24), maximum concentration (Cmax), and C24 geometric mean ratios were 1.36, 1.43, and 1.27, respectively. The pharmacokinetics of doravirine was not affected by multiple doses of dolutegravir (geometric mean ratios: 1.00, 0.98, and 1.06 for AUC0–24, C24, and Cmax, respectively). Both drugs were generally well tolerated.
The results of this study demonstrate that concomitant administration of doravirine and dolutegravir in healthy subjects causes no clinically significant alteration in the pharmacokinetic and safety profiles of the two drugs, thereby supporting further evaluation of co-administration of these agents for human immunodeficiency virus-1 treatment.
- 1.DHHS. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://aidsinfo.nih.gov/guidelines. Accessed 2016 March 25.
- 16.Gatell JM, Raffi F, Plettenberg A, et al. Efficacy and safety of doravirine 100 mg QD vs efavirenz 600 mg QD with TDF/FTC in ART-naive HIV-infected patients: week 24 results. 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention, July 18-22, 2015, Vancouver, Canada. TUAB0104. http://www.natap.org/2015/IAS/IAS_22.htm. Accessed 22 Sept 2016.
- 20.Sanchez RI, Fillgrove K, Hafey M, et al. In vitro evaluation of doravirine potential for pharmacokinetic drug interactions. https://issx.confex.com/issx/20NA/webprogram/Paper35163.html. Accessed 2016 March 25.
- 24.Yee KL, Chatterjee M, Dockendorf M, et al. Pharmacokinetics (PK) of doravirine and exposure-response analysis: efficacy and safety implications. In: 54th interscience conference on antimicrobial agents and chemotherapy (ICAAC), 5–9 Sept 2014, Washington, DC. http://www.natap.org/2014/ICAAC/ICAAC_04.htm. Accessed 28 Sept 2016.
- 26.TIVICAY (dolutegravir) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline. 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204790lbl.pdf. Accessed 25 Jan 2016.
- 29.Song I, Chen S, Piscitelli SC, Min S. Pharmacokinetics (PK) and PK-pharmacodynamic (PD) relationship of dolutegravir (DTG) in integrase inhibitor (INI)-naïve subjects. In: 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 10-13, 2013, Denver, CO. http://www.natap.org/2013/ICAAC/ICAAC_44.htm. Accessed 22 Sept 2016.
- 36.van Lunzen J, Maggiolo F, Arribas JR, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis. 2012;12:111–8.CrossRefPubMedGoogle Scholar